An interventional study of ACE (AI-Cirrhosis-ECG) 2.0 in Cirrhosis, sponsored by Mayo Clinic. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Mayo Clinic · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Fibrosis by Mayo Clinic — 4 open to participants now, 4 under way, none of them phase 3. Fibrosis · Mayo Clinic.
Among the 11 studies in Fibrosis by Mayo Clinic, this one is the only one that started in 2023, is one of 3 with no phase, and was the 9th registered.
1,272 studies on the registry are indexed under Fibrosis; 278 are open to participants now.
Browse Fibrosis studies →4 of the 11 studies in Fibrosis by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18–99
Mayo Clinic · Sites in United States
Ages 19+
Mayo Clinic · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18–75
By country, each count listing its studies:
Of the 197 Fibrosis studies recruiting now, 112 (57%) set no upper age limit and 53 (27%) stop at 75 or younger; 15 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 2
First in 1998; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 248 is above the median of 64 across 842 interventional studies indexed under Fibrosis.
Median enrollment 25 across the 7 interventional studies, 179 across the 4 observational. Of the 7 that completed or were terminated, 2 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
3 of the studies in Fibrosis by Mayo Clinic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06306963Mayo ClinicPrevalence of Gastric Motor Dysfunction and Upper GI Symptoms in Gastric Antral Vascular Ectasias | 2026-12-01 |
| NCT05477277Mayo ClinicAdverse Outcomes and Mortality in Liver Transplant | 2026-12-31 |
| NCT06425380Mayo ClinicPilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy | 2027-01-28 |
Add all 3 to your calendar (.ics) → With an account.
Among the 11 studies in Fibrosis by Mayo Clinic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overall objectives of this study are to determine the effectiveness of ACE 2.0 model in early detection of advanced liver fibrosis, and to determine the acceptance and barriers for use of an AI-enabled algorithm for prediction of liver disease in primary care.
A pragmatic, cluster randomized trial in 45 Mayo Clinic primary care practices will be conducted over a period of 6 months with 6 months of follow up. Care teams will be randomized 1:1 to intervention or usual care, stratified by region and patient volume. In the intervention arm, the DULCE score will be used to alert consenting providers to the likelihood of advanced liver disease with a recommendation for a FibroTest-ActiTest. The primary endpoint will be detection of advanced liver disease. Secondary outcomes will include completion of noninvasive fibrosis assessment tests and hepatology referral within 180 days of ECG, new diagnosis of liver disease stratified by etiology (nonalcoholic fatty liver disease, alcohol-associated liver disease, hepatitis C, and others) and severity (compensated with and without clinically-significant portal hypertension, and decompensated disease), initiation of prophylactic nonselective beta-blockers and imaging for hepatocellular carcinoma surveillance, according to published society guidelines. Post-study surveys to participating clinicians will be applied.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Criteria:
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Primary care providers will treat subject per standard of care
The ACE (AI-Cirrhosis-ECG) 2.0 will be used to alert primary care providers to the likelihood of advanced liver disease with a recommendation for laboratory tests.
Device: ACE (AI-Cirrhosis-ECG) 2.0
Patients will receive standard of care
Patients whose Clinician will be alerted by the ACE (AI-Cirrhosis-ECG) 2.0 to the likelihood of advanced liver disease with a recommendation for laboratory tests.
Device: ACE (AI-Cirrhosis-ECG) 2.0
An electrocardiogram (ECG) based artificial intelligence (AI) powered tool for detection of undiagnosed cirrhosis in primary care practices. And email alert is sent to providers which will display whether the ACE 2.0 result is positive or negative for the likelihood of advanced liver disease.
New Diagnosis of Advanced Chronic Liver Disease
The primary objective of this pragmatic trial is to validate a deep learning-based machine learning (ML) model for early detection of cirrhosis-associated signals on digitized ECG. The primary outcome is the number of participants with new diagnosis of advanced liver disease as assessed by a novel electrocardiogram-enabled convoluted neural network (CNN) compared to standard of care at 6 months.
Time frame: 6 months
Number of Participants to Not Complete Recommended Testing
The secondary objective is to assess barriers for adoption of an AI-enabled algorithm for detection of liver disease in routine community clinical practice. Number of participants to not complete the recommended testing according to the electrocardiogram-enabled CNN.
Time frame: 6 months
Primary care clinicians who care for adult patients (≥18 years), including physicians and advanced care practitioners, across 45 primary care practices in both urban and rural communities in Southern Minnesota and Wisconsin were eligible to participate.
| Milestone | Group 1: Usual Care Group-Clinician | Group 2: Electrocardiogram Machine Learning Group-Clinican | Group 3: Usual Care Group-Patients | Group 4: Electrocardiogram Machine Learning Group-Patients |
|---|---|---|---|---|
| Started | 122 | 126 | 7562 | 8034 |
| Completed | 122 | 123 | 7562 | 8034 |
| Not completed | 0 | 3 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 3 | 0 | 0 |
The primary objective of this pragmatic trial is to validate a deep learning-based machine learning (ML) model for early detection of cirrhosis-associated signals on digitized ECG. The primary outcome is the number of participants with new diagnosis of advanced liver disease as assessed by a novel electrocardiogram-enabled convoluted neural network (CNN) compared to standard of care at 6 months.
| Participants | Usual Care Group | Electrocardiogram Machine Learning Group |
|---|---|---|
| New Diagnosis of Advanced Chronic Liver Disease | 35 | 78 |
The secondary objective is to assess barriers for adoption of an AI-enabled algorithm for detection of liver disease in routine community clinical practice. Number of participants to not complete the recommended testing according to the electrocardiogram-enabled CNN.
| Participants | Group 1: Usual Care Group-Clinicians | Group 2: Electrocardiogram Machine Learning Group-Clinicians | Group 3: Usual Care Group-Patients | Group 4: Electrocardiogram Machine Learning Group-Patients |
|---|---|---|---|---|
| Number of Participants to Not Complete Recommended Testing | — | — | 7514 | 7764 |
Collected over Adverse events were not monitored or assessed for any clinician or patient.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: Usual Care Group-Clinicians | — | — | — |
| Group 2: Electrocardiogram Machine Learning Group-Clinicians | — | — | — |
| Group 3: Usual Care Group-Patients | — | — | — |
| Group 4: Electrocardiogram Machine Learning Group-Patients | — | — | — |
This is a pragmatic trial in which clinicians caring for adult primary care patients were consented and enrolled. Data analysis was conducted in their patients who underwent ECGs during the study period.
| Age, Continuous(years) | Group 1: Usual Care Group-Clinicians | Group 2: Electrocardiogram Machine Learning Group-Clinicians | Group 3: Usual Care Group-Patients | Group 4: Electrocardiogram Machine Learning Group-Patients | Total |
|---|---|---|---|---|---|
| Mean | 46.4 ± 10.3 | 45.7 ± 9.9 | 63.1 ± 18.6 | 63.8 ± 18.0 | 63.2 ± 18.3 |
| Sex/Gender, Customized(Participants) | Group 1: Usual Care Group-Clinicians | Group 2: Electrocardiogram Machine Learning Group-Clinicians | Group 3: Usual Care Group-Patients | Group 4: Electrocardiogram Machine Learning Group-Patients | Total |
|---|---|---|---|---|---|
| Female | 34 | 38 | 4427 | 3927 | 8426 |
| Male | 74 | 47 | 3135 | 4107 | 7363 |
| Prefer not to disclose | 3 | 3 | 0 | 0 | 6 |
| Unknown or Not Reported | 11 | 38 | 0 | 0 | 49 |
| Ethnicity (NIH/OMB)(Participants) | Group 1: Usual Care Group-Clinicians | Group 2: Electrocardiogram Machine Learning Group-Clinicians | Group 3: Usual Care Group-Patients | Group 4: Electrocardiogram Machine Learning Group-Patients | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 225 | 202 | 427 |
| Not Hispanic or Latino | 0 | 0 | 7228 | 7705 | 14933 |
| Unknown or Not Reported | 122 | 126 | 109 | 127 | 484 |
| Race (NIH/OMB)(Participants) | Group 1: Usual Care Group-Clinicians | Group 2: Electrocardiogram Machine Learning Group-Clinicians | Group 3: Usual Care Group-Patients | Group 4: Electrocardiogram Machine Learning Group-Patients | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 34 | 23 | 57 |
| Asian | 6 | 4 | 88 | 107 | 205 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 131 | 177 | 309 |
| White | 100 | 73 | 7175 | 7589 | 14937 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 16 | 48 | 134 | 138 | 336 |
| Region of Enrollment(participants) | Group 1: Usual Care Group-Clinicians | Group 2: Electrocardiogram Machine Learning Group-Clinicians | Group 3: Usual Care Group-Patients | Group 4: Electrocardiogram Machine Learning Group-Patients | Total |
|---|---|---|---|---|---|
| United States | 122 | 126 | 7562 | 8034 | 15844 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2023 to primary completion in Sep 2025, 28 months.
Results were first posted in Oct 2026, 1 year 1 month after primary completion.
Of 186 non-industry interventional studies with no phase under Fibrosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 57. This study's 28 months is below that.
Counting every sponsor, half of 195 studies reached it within 32 months; a quarter within 18 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.